


PHARMACEUTICAL 2017

ENDOCYTE INC Rank 87 of 313





PHARMACEUTICAL 2017

ENDOCYTE INC Rank 87 of 313

The relative strengths and weaknesses of ENDOCYTE INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDOCYTE INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 390% points. The greatest weakness of ENDOCYTE INC is the variable Revenues, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is -36%, being 380% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	140,256
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,562
Liabilities, Non-Current	2.9
Other Assets	34
Other Compr. Net Income	38
Other Expenses	0
Other Liabilities	782
Other Net Income	903
Property and Equipment	3,205
Research and Development	27,492
Revenues	0
Selling, General and Administrative Expense	17,298

Output Variable	Value in 1000 USD
Assets	143,494
Liabilities	6,347
Expenses	44,790
Stockholders Equity	137,147
Net Income	-43,888
Comprehensive Net Income	-43,868
Economic Capital Ratio	-36%